These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 23679223)

  • 1. Covalent inhibition of serine β-lactamases by novel hydroxamic acid derivatives.
    Tilvawala R; Pratt RF
    Biochemistry; 2013 May; 52(21):3712-20. PubMed ID: 23679223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Covalent Inhibitor of Class C β-Lactamases Reveals Extended Active Site Specificity.
    Tilvawala R; Cammarata M; Adediran SA; Brodbelt JS; Pratt RF
    Biochemistry; 2015 Dec; 54(50):7375-84. PubMed ID: 26651220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of action of a two-stage pro-inhibitor of serine β-lactamases.
    Tilvawala R; Pratt RF
    Biochemistry; 2013 Oct; 52(40):7060-70. PubMed ID: 24070199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics and mechanism of inhibition of a serine beta-lactamase by O-aryloxycarbonyl hydroxamates.
    Pelto RB; Pratt RF
    Biochemistry; 2008 Nov; 47(46):12037-46. PubMed ID: 18942857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penicillin acylase and O-aryloxycarbonyl hydroxamates: Two acyl-enzymes, one leading to hydrolysis, the other to inactivation.
    Adediran SA; Pratt RF
    Arch Biochem Biophys; 2017 Jan; 614():65-71. PubMed ID: 28038956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of serine amidohydrolases by complexes of vanadate with hydroxamic acids.
    Bell JH; Curley K; Pratt RF
    Biochem Biophys Res Commun; 2000 Aug; 274(3):732-5. PubMed ID: 10924345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of extended O-aryloxycarbonyl hydroxamates as inhibitors of a class C β-lactamase.
    Malico AA; Dave K; Adediran SA; Pratt RF
    Bioorg Med Chem; 2019 Apr; 27(7):1430-1436. PubMed ID: 30792103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O-aryloxycarbonyl hydroxamates: new beta-lactamase inhibitors that cross-link the active site.
    Wyrembak PN; Babaoglu K; Pelto RB; Shoichet BK; Pratt RF
    J Am Chem Soc; 2007 Aug; 129(31):9548-9. PubMed ID: 17628063
    [No Abstract]   [Full Text] [Related]  

  • 9. Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
    Weston GS; Blázquez J; Baquero F; Shoichet BK
    J Med Chem; 1998 Nov; 41(23):4577-86. PubMed ID: 9804697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of class D beta-lactamases by diaroyl phosphates.
    Majumdar S; Adediran SA; Nukaga M; Pratt RF
    Biochemistry; 2005 Dec; 44(49):16121-9. PubMed ID: 16331972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Lysine-Targeted Affinity Label for Serine-β-Lactamase Also Covalently Modifies New Delhi Metallo-β-lactamase-1 (NDM-1).
    Thomas PW; Cammarata M; Brodbelt JS; Monzingo AF; Pratt RF; Fast W
    Biochemistry; 2019 Jun; 58(25):2834-2843. PubMed ID: 31145588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward better antibiotics: crystallographic studies of a novel class of DD-peptidase/beta-lactamase inhibitors.
    Silvaggi NR; Kaur K; Adediran SA; Pratt RF; Kelly JA
    Biochemistry; 2004 Jun; 43(22):7046-53. PubMed ID: 15170342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different transition-state structures for the reactions of beta-lactams and analogous beta-sultams with serine beta-lactamases.
    Tsang WY; Ahmed N; Hinchliffe PS; Wood JM; Harding LP; Laws AP; Page MI
    J Am Chem Soc; 2005 Dec; 127(49):17556-64. PubMed ID: 16332108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic study of two novel enantiomeric tricyclic beta-lactams which efficiently inactivate class C beta-lactamases.
    Vilar M; Galleni M; Solmajer T; Turk B; Frère JM; Matagne A
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2215-23. PubMed ID: 11451677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases.
    Lassaux P; Hamel M; Gulea M; Delbrück H; Mercuri PS; Horsfall L; Dehareng D; Kupper M; Frère JM; Hoffmann K; Galleni M; Bebrone C
    J Med Chem; 2010 Jul; 53(13):4862-76. PubMed ID: 20527888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spirocyclopropyl beta-lactams as mechanism-based inhibitors of serine beta-lactamases. Synthesis by rhodium-catalyzed cyclopropanation of 6-diazopenicillanate sulfone.
    Sandanayaka VP; Prashad AS; Yang Y; Williamson RT; Lin YI; Mansour TS
    J Med Chem; 2003 Jun; 46(13):2569-71. PubMed ID: 12801220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of class A and class C beta-lactamases by penems: crystallographic structures of a novel 1,4-thiazepine intermediate.
    Nukaga M; Abe T; Venkatesan AM; Mansour TS; Bonomo RA; Knox JR
    Biochemistry; 2003 Nov; 42(45):13152-9. PubMed ID: 14609325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of the FEZ-1 metallo-beta-lactamase.
    Liénard BM; Horsfall LE; Galleni M; Frère JM; Schofield CJ
    Bioorg Med Chem Lett; 2007 Feb; 17(4):964-8. PubMed ID: 17157014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refined crystal structure of beta-lactamase from Citrobacter freundii indicates a mechanism for beta-lactam hydrolysis.
    Oefner C; D'Arcy A; Daly JJ; Gubernator K; Charnas RL; Heinze I; Hubschwerlen C; Winkler FK
    Nature; 1990 Jan; 343(6255):284-8. PubMed ID: 2300174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the chemistry of beta-lactam compounds as selected active-site serine beta-lactamase inhibitors.
    Mascaretti OA; Danelon GO; Laborde M; Mata EG; Setti EL
    Curr Pharm Des; 1999 Nov; 5(11):939-53. PubMed ID: 10539998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.